Corrigendum to “A mathematical model of tumor–immune interactions” (Journal of Theoretical Biology (2012) 294 (56–73), (S002251931100542X) (10.1016/j.jtbi.2011.10.027));A mathematical model of tumor-immune interactions

Journal of Theoretical Biology

Volumn 294, Issue , 2012, Pages 56-73

  Robertson Tessi, Mark ^a   El Kareh, Ardith ^a   Goriely, Alain ^b  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

IL 10; Immunosuppression; Regulatory T cells; TGF ; Tumor growth

Indexed keywords

CYTOKINE; GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA;

ANTIGEN; BLOOD; GROWTH RATE; IMMUNE RESPONSE; IMMUNE SYSTEM; MEDICINE; NUMERICAL MODEL; TUMOR;

ANTIGENICITY; ARTICLE; CANCER INCIDENCE; CELL INTERACTION; CELL KILLING; CELL METABOLISM; CELL POPULATION; CELL STIMULATION; CELL THERAPY; CELL TRANSPORT; DENDRITIC CELL; EFFECTOR CELL; HELPER CELL; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; IN VITRO STUDY; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; MATHEMATICAL PARAMETERS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; TUMOR ESCAPE; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR VOLUME;

EID: 81155144508     PISSN: 00225193     EISSN: 10958541     Source Type: Journal    
DOI: 10.1016/j.jtbi.2018.12.041     Document Type: Erratum

References (87)

1. Alleva D., Burger C., Elgert K. Tumor-induced regulation of suppressor macrophage nitric oxide and TNF-alpha production. Role of tumor-derived IL-10, TGF-Β, and prostaglandin E2. J. Immunol. 1994, 153:1674.
2. Ambrosi D., Mollica F. The role of stress in the growth of a multicell spheroid. J. Math. Biol. 2004, 48:477-499.
3. Anderson A., Chaplain M. Continuous and discrete mathematical models of tumor-induced angiogenesis. Bull. Math. Biol. 1998, 60:857-899.
4. von Andrian U., Mackay C. T-cell function and migration-two sides of the same coin. N. Engl. J. Med. 2000, 343:1020.
5. Arciero J., Jackson T., Kirschner D. A mathematical model of tumor-immune evasion and siRNA treatment. Discret. Contin. Dyn. Syst. Ser. B 2004, 4:39-58.
6. Arstila T., Casrouge A., Baron V., Even J., Kanellopoulos J., Kourilsky P. A direct estimate of the human αΒ T cell receptor diversity. Science 1999, 286:958.
7. Avradopoulos K., Mehta S., Blackinton D., Wanebo H. Interleukin-10 as a possible mediator of immunosuppressive effect in patients with squamous cell carcinoma of the head and neck. Ann. Surg. Oncol. 1997, 4:184-190.
8. Boissonnas A., Fetler L., Zeelenberg I., Hugues S., Amigorena S. In vivo imaging of cytotoxic T cell infiltration and elimination of a solid tumor. J. Exp. Med. 2007, 204:345.
9. Boon T., Cerottini J., Eynde B., Bruggen P., Pel A. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol. 1994, 12:337-365.
10. + T cell cytotoxic activity during adoptive T cell therapy in mice. J. Clin. Invest. 2008, 118:1390.
11. Brossart P., Wirths S., Stuhler G., Reichardt V., Kanz L., Brugger W. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 2000, 96:3102.
12. Byrne H., Preziosi L. Modelling solid tumour growth using the theory of mixtures. Math. Med. Biol. 2003, 20:341.
13. Chen L., McGowan P., Ashe S., Johnston J., Li Y., Hellstrom I., Hellstrom K. Tumor immunogenicity determines the effect of B7 costimulation on T-cell mediated tumor immunity. J. Exp. Med. 1994, 179:523.
14. Chouaib S., Asselin-Paturel C., Mami-Chouaib F., Caignard A., Blay J. The host-tumor immune conflict: from immunosuppression to resistance and destruction. Immunol. Today 1997, 18:493-497.
15. Curiel T. Tregs and rethinking cancer immunotherapy. J. Clin. Invest. 2007, 117:1167-1174.
16. Danforth D., Sgagias M. Tumor necrosis factor alpha enhances secretion of transforming growth factor Β2 in MCF-7 breast cancer cells. Clin. Cancer Res. 1996, 2:827.
17. De Boer R., Perelson A. T-cell repertoires and competitive exclusion. J. Theor. Biol. 1994, 169:375-390.
18. De Pillis L., Gu W., Fister K., Head T., Maples K., Murugan A., Neal T., Yoshida K. Chemotherapy for tumors: an analysis of the dynamics and a study of quadratic and linear optimal controls. Math. Biosci. 2007, 209:292-315.
19. De Pillis L., Gu W., Radunskaya A. Mixed immunotherapy and chemotherapy of tumors: modeling, applications and biological interpretations. J. Theor. Biol. 2006, 238:841-862.
20. Desser L., Holomanova D., Zavadova E., Pavelka K., Mohr T., Herbacek I. Oral therapy with proteolytic enzymes decreases excessive TGF-Β levels in human blood. Cancer Chemother. Pharmacol. 2001, 47:10-15.
21. Diefenbach A., Jensen E., Jamieson A., Raulet D. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 2001, 413:165-171.
22. Dudley M., Wunderlich J., Robbins P., Yang J., Hwu P., Schwartzentruber D., Topalian S., Sherry R., Restifo N., Hubicki A., et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002, 298:850.
23. Dunn G., Bruce A., Ikeda H., Old L., Schreiber R. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 2002, 3:991-998.
24. Dunn G., Koebel C., Schreiber R. Interferons, immunity and cancer immunoediting. Nat. Rev. Immunol. 2006, 6:836-848.
25. Fitzpatrick D., Bielefeldt-Ohmann H., Himbeck R., Jarnicki A., Marzo A., Robinson B. Tumour-induced immunosuppression and autocrine growth: use of inducible anti TGF-Β antisense RNA transfectants in a mesothelioma model. Lung Cancer 1996, 15:260.
26. Fong L., Engleman E. Dendritic cells in cancer immunotherapy. Annu. Rev. Immunol. 2000, 18:245-273.
27. Friberg S., Mattson S. On the growth rates of human malignant tumors: implications for medical decision making. J. Surg. Oncol. 1997, 65:284-297.
28. Frumento G., Piazza T., Di Carlo E., Ferrini S. Targeting tumor-related immunosuppression for cancer immunotherapy. Endocr. Metab. Immune Disord. Drug Targets 2006, 6:223-237.
29. Gastl G., Abrams J., Nanus D., Oosterkamp R., Silver J., Liu F., Chen M., Albino A., Bander N. Interleukin-10 production by human carcinoma cell lines and its relationship to interleukin-6 expression. Int. J. Cancer 1993, 55:96-101.
30. Gorelik L., Flavell R. Immune-mediated eradication of tumors through the blockade of transforming growth factor Β signaling in T cells. Nat. Med. 2001, 7:1118-1122.
31. Haring J., Pewe L., Perlman S. High-magnitude, virus-specific CD4 T-cell response in the central nervous system of coronavirus-infected mice. J. Virol. 2001, 75:3043.
32. Hart D., Shochat E., Agur Z. The growth law of primary breast cancer tumors as inferred from mammography screening trials. Br. J. Cancer 1998, 78:382-387.
33. + T-cell memory. Nat. Rev. Immunol. 2008, 8:107-119.
34. Hellstrom K., Hellstrom I. Principles of tumor immunity: tumor antigens. Biologic Therapy of Cancer: Principles and Practices 1991, 35-52. J.B. Lippincott, Philadelphia. V. De Vita, S. Hellman, S. Rosenberg (Eds.).
35. Hellstrom K., Hellstrom I. Lymphocyte-mediated cytotoxicity and blocking serum activity to tumor antigens. Adv. Immunol. 1974, 18:209-277.
36. Hsieh C., Chen D., Hwang L. Tumor-induced immunosuppression: a barrier to immunotherapy of large tumors by cytokine-secreting tumor vaccine. Hum. Gene Ther. 2000, 11:681-692.
37. Iwashita I., Ueyama T., Iwashita A., Kawamoto K., Kitagawa S., Motooka M., Utsunomiya T., Masuda K. Natural history of colorectal carcinoma: can the tumor volume doubling time be predicted by radiologic findings or immunohistochemical variables?. J. Surg. Oncol. 1998, 68:215.
38. Jackson C., Talpos G., Block M., Norum R., Lloyd R., Tashjian A. Clinical value of tumor doubling estimations in multiple endocrine neoplasia type II. Surgery 1984, 96:981-987.
39. Jain R., Ward-Hartley K. Tumor blood flow: characterization, modifications, and role in hyperthermia. IEEE Trans. Sonics Ultrason. 1984, 31:504-526.
40. Jameson S. Maintaining the norm: T-cell homeostasis. Nat. Rev. Immunol. 2002, 2:547-556.
41. + regulatory T cells. J. Immunol. 2006, 177:896.
42. Kim H., Han M., Do K., Kim K., Choi H., Kim A., Sung M., Chang K. Volume of cervical lymph nodes using 3D ultrasonography. Differentiation of metastatic from reactive lymphadenopathy in primary head and neck malignancy. Acta Radiol. 2002, 43:571.
43. Kirschner D., Panetta J. Modeling immunotherapy of the tumor-immune interaction. J. Math. Biol. 1998, 37:235-252.
44. Kobie J., Akporiaye E. Immunosuppressive role of transforming growth factor beta in breast cancer. Clin. Appl. Immunol. Rev. 2003, 3:277-287.
45. Konrad M., Hemstreet G., Hersh E., Mansell P., Mertelsmann R., Kolitz J., Bradley E. Pharmacokinetics of recombinant interleukin 2 in humans. Cancer Res. 1990, 50:2009.
46. Kripke M. Antigenicity of murine skin tumors induced by ultraviolet light. J. Natl. Cancer Inst. 1974, 53:1333.
47. Kuznetsov V., Makalkin I., Taylor M., Perelson A. Nonlinear dynamics of immunogenic tumors: parameter estimation and global bifurcation analysis. Bull. Math. Biol. 1994, 56:295-321.
48. + regulatory T-cell suppression of dendritic cell function involves TGF-Β and IL-10. Cancer Immunol. Immunother. 2007, 56:48-59.
49. Le T., Leung L., Carroll W., Schibler K. Regulation of interleukin-10 gene expression: possible mechanisms accounting for its upregulation and for maturational differences in its expression by blood mononuclear cells. Blood 1997, 89:4112.
50. + T cells impinge on tumor immunobiology? On the existence of two alternative dynamical classes of tumors. J. Theor. Biol. 2007, 247:122-137.
51. Liu K., Waskow C., Liu X., Yao K., Hoh J., Nussenzweig M. Origin of dendritic cells in peripheral lymphoid organs of mice. Nat. Immunol. 2007, 8:578-583.
52. + T regulatory cells: role of tumor-derived TGF-Β. J. Immunol. 2007, 178:2883.
53. Liyanage U., Moore T., Joo H., Tanaka Y., Herrmann V., Doherty G., Drebin J., Strasberg S., Eberlein T., Goedegebuure P., et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J. Immunol. 2002, 169:2756.
54. Lotze M., Frana L., Sharrow S., Robb R., Rosenberg S. In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2. J. Immunol. 1985, 134:157.
55. + T-cell survival, division, and IL-2 production: a role for T-cell intrinsic Smad3. J. Immunol. 2005, 174:2071.
56. Mempel T., Henrickson S., Von Andrian U. T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases. Nature 2004, 427:154-159.
57. Norton L. A Gompertzian model of human breast cancer growth. Cancer Res. 1988, 48:7067-7071.
58. Peer P., Van Dijck J., Verbeek A., Hendriks J., Holland R. Age-dependent growth rate of primary breast cancer. CA Cancer J. Clin. 1993, 71:3547-3551.
59. + immunoregulatory cells. J. Immunol. 2001, 167:1137.
60. de Pillis L., Radunskaya A., Wiseman C. A validated mathematical model of cell-mediated immune response to tumor growth. Cancer Res. 2005, 65:7950.
61. Roitt I., Delves P. Roitt's Essential Immunology 2001, Blackwell Science Inc., Oxford.
62. Romani N., Inaba K., Puré E., Crowley M., Witmer-Pack M., Steinman R. A small number of anti-CD3 molecules on dendritic cells stimulate DNA synthesis in mouse T lymphocytes. J. Exp. Med. 1989, 169:1153.
63. Roose T., Chapman S., Maini P. Mathematical models of avascular tumor growth. SIAM Rev. 2007, 49:179-208.
64. Rosenberg S., Lotze M. Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes. Annu. Rev. Immunol. 1986, 4:681-709.
65. Rosenberg S., Spiess P., Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986, 233:1318.
66. Seddiki N., Santner-Nanan B., Tangye S., Alexander S., Solomon M., Lee S., Nanan R., de Saint Groth B. Persistence of naive CD45RA+ regulatory T cells in adult life. Blood 2006, 107:2830.
67. + regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J. Exp. Med. 2005, 201:723.
68. Skipper H. Kinetics of mammary tumor cell growth and implications for therapy. Cancer 1971, 28:1479-1499.
69. Skog A., Wadhwa M., Hassan M., Gharizadeh B., Bird C., Ragnhammar P., Thorpe R., Mellstedt H. Alteration of interleukin 2 (IL-2) pharmacokinetics and function by IL-2 antibodies induced after treatment of colorectal carcinoma patients with a combination of monoclonal antibody 17-1A, granulocyte macrophage colony-stimulating factor, and IL-2. Clin. Cancer Res. 2001, 7:1163.
70. + T-cell immunity. Nat. Immunol. 2004, 5:1143-1148.
71. Steele G. Growth Kinetics of Tumors 1977, Clarendon, Oxford.
72. Taga K., Mostowski H., Tosato G. Human interleukin-10 can directly inhibit T-cell growth. Blood 1993, 81:2964.
73. Tannock I., Lee C., Tunggal J., Cowan D., Egorin M. Limited penetration of anticancer drugs through tumor tissue. Clin. Cancer Res. 2002, 8:878.
74. Taylor J., Fahey J., Detels R., Giorgi J. CD4 percentage, CD4 number, and CD4:CD8 ratio in HIV infection: which to choose and how to use. J. Acquired Immune Defic. Syndr. 1989, 2:114.
75. Thomas D., Massagué J. TGF-Β directly targets cytotoxic T-cell functions during tumor evasion of immune surveillance. Cancer Cell 2005, 8:369-380.
76. Vaage J. Concomitant immunity and specific depression of immunity by residual or reinjected syngeneic tumor tissue. Cancer Res. 1971, 31:1655.
77. + regulatory T cells promotes a tumor-specific immune response in pancreas cancer-bearing mice. Ann. Surg. Oncol. 2006, 13:1252-1258.
78. Villunger A., Strasser A. The great escape: is immune evasion required for tumor progression?. Nat. Med. 1999, 5:874-875.
79. hi Foxp3 regulatory T cells are derived by rapid turnover of memory populations in vivo. J. Clin. Invest. 2006, 116:2423-2433.
80. + T cell clones and resting T cells. Specific inhibition of IL-2 production and proliferation. J. Immunol. 1993, 150:4754.
81. Wakefield L., Winokur T., Hollands R., Christopherson K., Levinson A., Sporn M. Recombinant latent transforming growth factor Β1 has a longer plasma half-life in rats than active transforming growth factor Β1, and a different tissue distribution. J. Clin. Invest. 1990, 86:1976.
82. Waterhouse N., Sutton V., Sedelies K., Ciccone A., Jenkins M., Turner S., Bird P., Trapani J. Cytotoxic T lymphocyte-induced killing in the absence of granzymes A and B is unique and distinct from both apoptosis and perforin-dependent lysis. J. Cell Biol. 2006, 173:133.
83. Wimmer C., Rentsch M., Crispin A., Illner W., Arbogast H., Graeb C., Jauch K., Guba M. The janus face of immunosuppression-de novo malignancy after renal transplantation: the experience of the Transplantation Center Munich. Kidney Int. 2007, 71:1271-1278.
84. Wojtowicz-Praga S. Reversal of tumor-induced immunosuppression by TGF-Β inhibitors. Invest. New Drugs 2003, 21:21-32.
85. Wolf A., Wolf D., Steurer M., Gastl G., Gunsilius E., Grubeck-Loebenstein B. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin. Cancer Res. 2003, 9:606.
86. + T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 2001, 61:4766.
87. Yates A., Callard R. Cell death and the maintenance of immunological memory. Discret. Contin. Dyn. Syst. 2001, 1:43-59.